Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results
ACCESSWIRE•07/08/2026•09:00 ET
0
Whiz Insights
BioVie CEO Cuong Do to discuss the newly released Phase 2 SUNRISE-PD results and what they mean for the future development of bezisterim in Parkinson's disease
Learn how the BioVie's differentiated approach to targeting neuroinflammation and insulin resistance could position bezisterim as a potential first-line therapy in early-stage Parkinson's disease
Get started
Create a free account to read the full story.